Biomarker · Gene alteration

BCR-ABL1 fusion (Philadelphia chromosome)

The BCR-ABL1 fusion from t(9;22) detected by karyotype, FISH or quantitative RT-PCR of blood or marrow; the defining diagnostic marker of chronic myeloid leukemia, a predictive marker for ABL tyrosine kinase inhibitors, and a molecular-response marker.

CI-BIO-00000052ABL1 graph →BCR graph →NCIt C94600

Also calledBCR-ABL1 · BCR::ABL1 · Philadelphia chromosome · Ph+ · t(9;22) · p210 · p190

Derived

Associated cancers (6)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Chronic Myeloid Leukemia, BCR-ABL1 Positive	297	293	—	4	4 / 26 / 146 / 121 / 0
Malignant Neoplasm	22	22	—	—	0 / 0 / 0 / 22 / 0
Acute Lymphoblastic Leukemia	6	6	—	—	0 / 0 / 4 / 2 / 0
B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	4	—	—	4	0 / 4 / 0 / 0 / 0

Derived

Drugs with predictive evidence (8)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
DasatinibSmall Molecule	106	14	92	A	9 / 47	Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Malignant Neoplasm
Imatinib MesylateSmall Molecule	67	—	67	B

Curated evidence

Predictive evidence items (323)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–100 of 323 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 G250E + ABL1 Fusion3
Bosutinib

Regulatory

Approvals mentioning the linked drugs (209)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (39)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 19 recruiting · 5 active phase 3 · 223 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–39 of 39 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07269470	Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	recruiting	Phase 2

Literature

Linked publications (32)

Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 32 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
· Blood · 2008 · PMID 18818391 · validated civic_curation pubmed
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
· Biologics · 2014 · PMID 25349473 · validated

ABL1 Y253H + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	2	accepted	EID4331 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	3	accepted	EID4332 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Does Not Support Resistance	3	accepted	EID4335 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

ABL1 E255K + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	1	accepted	EID4347 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	1	accepted	EID4348 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Does Not Support Resistance	3	accepted	EID4350 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

ABL1 T315I + ABL1 Fusion4
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	2	accepted	EID4362 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	2	accepted	EID4364 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Supports Resistance	3	accepted	EID4365 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Supports Resistance	2	accepted	EID4368 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the T315I mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=13) were associated with acquired resistant t… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC	civic

ABL1 F317L + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	3	accepted	EID4381 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Reduced Sensitivity	1	accepted	EID4382 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Supports Resistance	5	accepted	EID637 BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML. PMID 18818391 · Jabbour et al., 2008 · Open in CIViC	civic

ABL1 M351T + ABL1 Fusion2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Reduced Sensitivity	1	accepted	EID4394 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Does Not Support Resistance	4	accepted	EID4396 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02481502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02360810) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 2, 2011	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02360829) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 29, 2011	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02320193) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 4, 2009	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293145) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293137) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as SPRYCEL (DIN 02293129) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2007	health-canada-dpd
Dasatinib	EU EMA	—	Dasatinib Accord Healthcare is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.  Dasatinib Accord Healthcare is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ ALL in combination with chemotherapy.	approved	Jul 26, 2024	ema
Dasatinib	EU EMA	—	Dasatinib Accordpharma is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Dasatinib Accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ ALL in combination with chemotherapy.	withdrawn	Mar 24, 2022	ema
Dasatinib	EU EMA	Acute Lymphoblastic Leukemia	Dasatinib Accord is indicated for the treatment of adult patients with: • Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. Dasatinib Accord is indicated for the treatment of paediatric patients with: • newly diagnosed Ph+ ALL in combination with chemotherapy.	withdrawn	Mar 24, 2022	ema
Dasatinib	EU EMA	—	Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.	approved	Nov 20, 2006	ema
Dasatinib	US FDA	—	Efficacy supplement 2025-08-01 (see label)	approved	Aug 1, 2025	openfda
Dasatinib	US FDA	—	1. INDICATIONS AND USAGE PHYRAGO is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. PHYRAGO is indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. PHYRAGO TM is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )	approved	Dec 5, 2023	openfda
Dasatinib	US FDA	—	Efficacy supplement 2018-12-21 (see label)	approved	Dec 21, 2018	openfda
Dasatinib	US FDA	—	Efficacy supplement 2017-11-09 (see label)	approved	Nov 9, 2017	openfda
Dasatinib	US FDA	—	Efficacy supplement 2015-08-12 (see label)	approved	Aug 12, 2015	openfda
Dasatinib	US FDA	—	Efficacy supplement 2013-06-17 (see label)	approved	Jun 17, 2013	openfda
Dasatinib	US FDA	—	Efficacy supplement 2010-10-28 (see label)	approved	Oct 28, 2010	openfda
Dasatinib	US FDA	—	Efficacy supplement 2010-10-28 (see label)	approved	Oct 28, 2010	openfda
Dasatinib	US FDA	—	Efficacy supplement 2009-05-21 (see label)	approved	May 21, 2009	openfda
Dasatinib	US FDA	—	Efficacy supplement 2007-11-08 (see label)	approved	Nov 8, 2007	openfda
Dasatinib	US FDA	—	Efficacy supplement 2007-11-08 (see label)	approved	Nov 8, 2007	openfda
Dasatinib	US FDA	—	Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1 , 14) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (1 , 14)	approved	Jun 28, 2006	openfda
Imatinib	CA Health Canada	—	Marketed in Canada as IMATINIB (DIN 02521210) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 29, 2024	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as IMATINIB (DIN 02521202) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 29, 2024	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as JAMP IMATINIB (DIN 02495074) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 31, 2025	Apr 27, 2021	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as JAMP IMATINIB (DIN 02495066) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 31, 2025	Apr 27, 2021	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as IMATINIB (DIN 02504596) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 7, 2021	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as IMATINIB (DIN 02504618) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 7, 2021	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as ACH-IMATINIB (DIN 02490994) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 24, 2020	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as ACH-IMATINIB (DIN 02490986) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 24, 2020	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MINT-IMATINIB (DIN 02492342) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 19, 2020	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MINT-IMATINIB (DIN 02492334) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 19, 2020	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as PMS-IMATINIB (DIN 02431122) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince May 16, 2018	May 26, 2015	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as PMS-IMATINIB (DIN 02431114) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 24, 2020	May 26, 2015	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as NAT-IMATINIB (DIN 02397293) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 29, 2014	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as NAT-IMATINIB (DIN 02397285) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 29, 2014	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as TEVA-IMATINIB (DIN 02399814) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 22, 2013	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as APO-IMATINIB (DIN 02355337) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 19, 2013	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as APO-IMATINIB (DIN 02355345) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 19, 2013	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as TEVA-IMATINIB (DIN 02399806) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 2, 2013	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as GLEEVEC (DIN 02253275) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 5, 2005	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as GLEEVEC (DIN 02253283) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 25, 2004	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as GLEEVEC (DIN 02244725) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 24, 2008	Sep 26, 2001	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as SANDOZ IMATINIB (DIN 02515547) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 25, 2023	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as SANDOZ IMATINIB (DIN 02515555) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 25, 2023	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MYLAN-IMATINIB (DIN 02424495) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MYLAN-IMATINIB (DIN 02424509) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as TARO-IMATINIB (DIN 02428318) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as TARO-IMATINIB (DIN 02428326) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd